

# CHEMO PHARMA LABORATORIES LIMITED

Registered Office: 5-Kumud Apartment Co. Op. HSG. SOC. Ltd., Karnik Road, Chikan Ghar, Kalyan, Dist. Thane - 421301

• Corporate Office : - Empire House, 3<sup>rd</sup> Floor, 214, Dr. D. N. Road, Fort, Mumbai - 400 001

• Tel.No. (022) 22078381, 22078382 • Fax No.: (022) 22074294 • CIN No.: L99999MH1942PLC003556 • PAN NO.: AAACC2056K

Website: www.thechemopharmalaboratoriesltd.com • Email ID: chemopharmalab@gmail.com

Date: 26<sup>th</sup> July, 2021

To,  
Bombay Stock Exchange Limited  
Department of Corporate Services,  
25<sup>th</sup> Floor, P. J. Towers, Dalal Street,  
Mumbai-400001

Script ID : 506365

Subject : SUBMISSION OF COMPLIANCES UNDER SECURITIES AND EXCHANGE BOARD OF INDIA (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015

Dear Sirs,

We are enclosing herewith Quarterly Compliances pursuant to Securities And Exchange Board of India (Listing Obligations And Disclosure Requirements) Regulations, 2015 for Quarter ended 30<sup>th</sup> June, 2021 as under -


1.	Regulation 33	Un-audited Quarterly Financial Results for the Quarter ended 30/06/2021 along with Limited Review Report issued by our Auditors, M/s. VMD & Co., Chartered Accountant, Mumbai
2.		Outcome of the Board Meeting Held on 26/07/2021

You are requested to take this on your records.

Thanking You.

Yours Faithfully,

FOR CHEMO PHARMA LABORATORIES LIMITED

  
ASHOK SOMANI  
DIRECTOR  
(DIN - 03063364)



Encl: as above  
Place: Mumbai



**LIMITED REVIEW REPORT**

We have reviewed the accompanying Statement of unaudited financial results of **M/S CHEMO PHARMA LABORATORIES LTD.**, Mumbai for the quarter ended **30<sup>th</sup> June 2021**. This Statement is the responsibility of the Company's management and has been approved by the Board of Directors / committee of Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2400, Engagement to Review Financial Statements issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our notice that causes us to believe that the accompanying Statement of unaudited financial results prepared in accordance with applicable Accounting Standards and other recognized accounting practices and polices has not disclosed the information required to be disclosed in terms of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For M/s VMD & Co.  
Chartered Accountants  
FRN: 125002W

CA Amit Ganpule  
Partner  
MRN: 114222



Dated: July 16, 2021

Place: Mumbai

UDIN: 21114222AAAALH2117

# CHEMO PHARMA LABORATORIES LIMITED

Registered Office: 5-Kumud Apartment Co. Op. HSG. SOC. Ltd., Karnik Road, Chikan Ghar, Kalyan, Dist. Thane - 421301

• Corporate Office : - Empire House, 3<sup>rd</sup> Floor, 214, Dr. D. N. Road, Fort, Mumbai - 400 001

• Tel.No. (022) 22078381, 22078382 • Fax No.: (022) 22074294 • CIN No.: L99999MH1942PLC003556 • PAN NO.: AAACC2056K

Website: www.thechemopharmalaboratoriesltd.com • Email ID: chemopharmalab@gmail.com

## STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE 2021

Sr. No.	Particulars	(Rupees in Thousand)			
		Quarter Ended			Year Ended
		30th June 2021	31st March 2021	30th June 2020	31st March 2021
		Unaudited	Unaudited	Unaudited	Audited
I	Revenue from Operations				
II	Other Income				-
III	<b>Total Revenue (I + II)</b>	1,092	2,574	1,563	6,680
IV	<b>Expenses</b>	1,092	2,574	1,563	6,680
	(1) Cost Materials consumed	-	-	-	-
	(2) Purchase of Stock-in-Trade	-	-	-	-
	(3) Changes in Inventories of Finished Goods, Work-in-Progress and Stock-in-Trade	-	-	-	-
	(4) Employee Benefits Expenses	352	367	245	1,262
	(5) Depreciation and Amortisation Expenses	-	239	-	239
	(6) Administrative and Other Expenses	429	1,194	431	2,071
	(7) Finance Costs	-	-	-	-
	<b>Total Expenses</b>	781	1,800	676	3,572
V	<b>Profit/(Loss) before Exceptional and Extra ordinary Items and tax (III - IV)</b>	311	774	887	3,108
VI	Exceptional Items	-	-	-	-
VII	<b>Net Profit/(Loss) before Extra ordinary Items and Tax (V - VI)</b>	311	774	887	3,108
VIII	Extra Ordinary Items	-	-	-	-
IX	<b>Profit/(Loss) before Tax (VII-VIII)</b>	311	774	887	3,108
X	Tax Expenses				
	(1) Current Tax	-	503	-	503
	(2) Tax Adjustment Previous Year	-	104	56	104
	(3) Deferred Tax	-	-	-	-
XI	Profit/(Loss) for the period from continuing operations (IX - X)	311	167	831	2,501
XII	Profit/(Loss) from discontinuing operations	-	-	-	-
XIII	Tax Expenses of discontinuing operations	-	-	-	-
XIV	Profit/(Loss) from discontinuing operations (after tax) (XII - XIII)	-	-	-	-
XV	<b>Profit/(Loss) for the period (XI - XIV)</b>	311	167	831	2,501
XVI	Other Comprehensive Income				
	A (i) Items that will not be reclassified to profit or loss				
	(ii) Income tax relating to items that will not be reclassified to profit or loss				
	B (i) Items that will not be reclassified to profit or loss				
	(ii) Income tax relating to items that will not be reclassified	-	-	-	-
XVII	Total Comprehensive Income for the period (XV+XVI) (Comprising Profit (Loss) and Other Comprehensive Income for the period)	311	167	831	2,501
XVIII	<b>Earnings per Share :</b>				
	(1) Basic	0.21	0.11	0.55	1.67
	(2) Diluted				

### Notes :

- This Statement has been prepared in accordance with the Companies (Indian Accounting Standard) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 read with Rule 3 of the Companies (Indian Accounting Standard) Rules, 2015 and Companies (Indian Accounting Standard) Accounting Rules, 2016.
- The above Standalone Unaudited Financial Results for the Quarter Ended 30.06.2021 have been reviewed by the Audit Committee in their Meeting held on 26.07.2021 and approved by the Board of Directors of its Meeting held on 26.07.2021. The Limited Review Report of Auditors M/s VMD & Co. was also taken on record by the Board in its Meeting.
- The Company is not having any Subsidiary Company.
- The Company is having only one Segment and no other reportable segment in terms of Ind AS 108 in 'Operating Segment'.



For Chemo - Pharma Laboratories Limited

*Ashok Somani*  
Ashok Somani

Director  
DIN : 03063364

Place : Mumbai  
Date : 26th July, 2021

# CHEMO PHARMA LABORATORIES LIMITED

Registered Office: 5-Kumud Apartment Co. Op. HSG. SOC. Ltd., Karnik Road, Chikan Ghar, Kalyan, Dist. Thane - 421301

• Corporate Office : - Empire House, 3<sup>rd</sup> Floor, 214, Dr. D. N. Road, Fort, Mumbai - 400 001

• Tel.No. (022) 22078381, 22078382 • Fax No.: (022) 22074294 • CIN No.: L99999MH1942PLC003556 • PAN NO.: AAACC2056K

Website: www.thechemopharmalaboratoriesltd.com • Email ID: chemopharmalab@gmail.com

## RECONCILIATION OF STANDALONE NET PROFIT FOR THE QUARTER ENDED 30TH JUNE, 2021

(Rs. in Thousand)

PARTICULARS	STANDALONE		
	UNAUDITED QUARTER ENDED 30.06.2021	UNAUDITED QUARTER ENDED 30.06.2020	AUDITED YEAR ENDED 31.03.2021
Reconciliation of Profit After Tax as reported earlier:			
Net Profit / (Loss) for the Period (as per AS)	311	831	2,501
Benefit / (Charge):	-	-	-
Impact of Deferred Income (Government Grant) Amortized to Income	-	-	-
Impact of Fair Valuation of Financial Instruments	-	-	-
Impact of Actuarial Gain / Loss Taken OCI	-	-	-
Impact of Adjustment of Deferred Tax	-	-	-
Net Profit / (Loss) for the Period (as per AS)	311	831	2,501

For Chemo Pharma Laboratories Ltd.



*Ashok Somani*

Ashok Somani

Director

DIN : 03063364

Mumbai, 26th July, 2021